Meeting
2022 ASCO Annual Meeting
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in subjects with solid tumors.
Authors
Diwakar Davar
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA
Diwakar Davar , John D. Powderly , Susanna Varkey Ulahannan , Melissa Lynne Johnson , Manish Sharma , John C. Krauss , Robert Stagg , Brian Francica , Anne Moon , Yonchu Jenkins , Peppi Prasit , Thomas Walter Dubensky Jr., Sam H. Whiting , Kyriakos P. Papadopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04344795
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2696)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2696
Abstract #
TPS2696
Poster Bd #
335b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Susanna Varkey Ulahannan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2018 ASCO Annual Meeting
Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
First Author: Andreea Varga
Poster
2015 ASCO Annual Meeting
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
First Author: Kathleen N. Moore